Key Metrics
0.89
5-Year SI
5-year SI
- N/A 2-year SI
- 0.89 Lifetime SI
Scite Index
Scite Index
scite Index is the ratio of citations supporting research which is published in the journal to sum of citations either supporting or contrasting the research published in the journal for the same time period. Minimum 100 supporting citations required.
Q4
Hematology
SJR
- Q3 Hematology
- Q4 Immunology and Allergy
SJR
SJR
SCImago Journal Rank measures weighted citations received by the serial. Citation weighting depends on subject field and prestige (SJR) of the citing serial.
Topics Covered
- Seborrheic keratosis
- Surgical patients
- Ferritin
- Anemia
- Hematopoietic stem cell transplantation
- Cold Agglutinin
- Questionnaire
- Thrombotic thrombocytopenic purpura
- Prognostic score
- Preoperative anemia
- Inventory management
- Acute leukemia
- Systematic review
- Daratumumab
- Mean platelet volume
- Induction therapy
- Acute chest syndrome
- Clinical case
- Cohort study
- Hemophagocytic lymphohistiocytosis
Journal Specifications
| Overview | |
| Publisher | ELSEVIER |
| Language | English |
| Frequency | Quarterly |
| General Details | |
| Language | English |
| Frequency | Quarterly |
| Publication Start Year | 2018 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Publication ID scheme | DOI |
Planning to publish in HEMATOLOGY TRANSFUSION AND CELL THERAPY ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Looking for the right journals to submit your mansucript?
Upload your manuscript and get a submission readiness score and other journal recommendations.
Check my PaperRecently Published Papers
-
Full paper
TRATAMENTO DA LEUCEMIA MIELÓIDE CRÔNICA COM INIBIDORES DE TIROSINO QUINASE EM SEGUNDA LINHA
- 1 Oct 21
- Hematology, Transfusion and Cell Therapy
-
Full paper
OUTCOMES OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) ACCORDING TO THE REASONS FOR INITIATION OF FIRST-LINE TREATMENT: A RETROSPECTIVE ANALYSIS OF THE BRAZILIAN REGISTRY OF CLL
- 1 Oct 21
- Hematology, Transfusion and Cell Therapy
-
Full paper
EVOLUÇÃO DOS CANDIDATOS À DOAÇÃO DE SANGUE DO GÊNERO FEMININO NO BANCO DE SANGUE DO HOSPITAL SANTA MARCELINA EM 10 ANOS
- 1 Oct 21
- Hematology, Transfusion and Cell Therapy
-
Full paper
SUBGROUP ANALYSES OF ELDERLY PATIENTS AGED 70 YEARS IN MAGNIFY: A PHASE 3B INTERIM ANALYSIS OF INDUCTION R2 FOLLOWED BY MAINTENANCE IN RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA
- 1 Oct 21
- Hematology, Transfusion and Cell Therapy
-
Full paper
RECIDIVA DE LEUCEMIA MIELOIDE AGUDA (LMA) COM ACOMETIMENTO EM SISTEMA NERVOSO CENTRAL (SNC): RELATO DE CASO
- 1 Oct 21
- Hematology, Transfusion and Cell Therapy
-
Full paper
TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D (GPRC5D) CD3 BISPECIFIC ANTIBODY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED PHASE 1 STUDY RESULTS
- 1 Oct 21
- Hematology, Transfusion and Cell Therapy
Scite analysis
Powered by scite_
6k articles received 2.6k citations see all
- 143 Supporting
- 2,116 Mentioning
- 16 Contrasting
Editorial notices
- 1 Retractions
- 2 Withdrawals
- 0 Corrections
- 2 Errata
- 0 Expression of Concern
FAQs
How long has HEMATOLOGY TRANSFUSION AND CELL THERAPY been actively publishing?
HEMATOLOGY TRANSFUSION AND CELL THERAPY has been in operation since 2018 till date.
What is the publishing frequency of HEMATOLOGY TRANSFUSION AND CELL THERAPY ?
HEMATOLOGY TRANSFUSION AND CELL THERAPY published with a Quarterly frequency.
How many articles did HEMATOLOGY TRANSFUSION AND CELL THERAPY publish last years ?
In 2023, HEMATOLOGY TRANSFUSION AND CELL THERAPY published articles.
What is the eISSN & pISSN for HEMATOLOGY TRANSFUSION AND CELL THERAPY ?
For HEMATOLOGY TRANSFUSION AND CELL THERAPY,eISSN is 2531-1379 and pISSN is2531-1379.
What is the SJR for HEMATOLOGY TRANSFUSION AND CELL THERAPY ?
SJR for HEMATOLOGY TRANSFUSION AND CELL THERAPY is Q4.
Who is the publisher of HEMATOLOGY TRANSFUSION AND CELL THERAPY ?
ELSEVIER is the publisher of HEMATOLOGY TRANSFUSION AND CELL THERAPY.